Melanoma prognosis and staging

2007 ◽  
pp. 371-394
Keyword(s):  
Melanoma Prognosis

Polymorphisms in apoptosis-related genes in cutaneous melanoma prognosis: sex disparity

2017 ◽  
Vol 34 (2) ◽  
Author(s):  
Cristiane Oliveira ◽  
Gustavo Jacob Lourenço ◽  
José Augusto Rinck-Junior ◽  
Aparecida Machado de Moraes ◽  
Carmen Silvia Passos Lima
Keyword(s):  
Cutaneous Melanoma ◽  
Melanoma Prognosis ◽  
Sex Disparity

scholarly journals Serum Selenium Level and 10-Year Survival after Melanoma

Biomedicines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 991
Author(s):  
Emilia Rogoża-Janiszewska ◽  
Karolina Malińska ◽  
Piotr Baszuk ◽  
Wojciech Marciniak ◽  
Róża Derkacz ◽  
...  
Keyword(s):  
Selenium Level ◽  
Serum Selenium ◽  
Lower Survival Rate ◽  
Treatment Regimens ◽  
Melanoma Diagnosis ◽  
Serum Selenium Levels ◽  
Melanoma Prognosis ◽  
Level I ◽  
Low Selenium ◽  
Serum Selenium Level

Melanoma is one of the most aggressive human malignancies. The determination of prognostic biomarkers is important for the early detection of recurrence and for the enrollment of the patients into different treatment regimens. Herein, we report the 10-year survival of 375 melanoma patients depending on their serum selenium levels. The study group was followed up from the date of melanoma diagnosis until death or 2020. Patients were assigned to one of four categories, in accordance with the increasing selenium level (I–IV quartiles). The subgroup with low selenium levels had a significant lower survival rate in relation to patients with high selenium levels, HR = 8.42; p = 0.005 and HR = 5.83; p = 0.02, for uni- and multivariable models, respectively. In the univariable analysis, we also confirmed the association between Breslow thickness, Clark classification and age at melanoma prognosis. In conclusion, a low serum selenium level was associated with an increased mortality rate in the 10 years following melanoma diagnosis. Future studies in other geographic regions with low soil selenium levels should be conducted to confirm our findings.

scholarly journals Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition

2020 ◽  
Vol 112 (9) ◽  
pp. 921-928 ◽  
Author(s):  
Shirin Bajaj ◽  
Douglas Donnelly ◽  
Melissa Call ◽  
Paul Johannet ◽  
Una Moran ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Statistical Tests ◽  
Area Under The Curve ◽  
Cancer Staging ◽  
Stage I ◽  
Stage Iii ◽  
Prognostic Accuracy ◽  
American Joint Committee ◽  
Melanoma Prognosis ◽  
Eighth Edition

Abstract Background The American Joint Committee on Cancer (AJCC) maintains that the eighth edition of its Staging Manual (AJCC8) has improved accuracy compared with the seventh (AJCC7). However, there are concerns that implementation may disrupt analysis of active clinical trials for stage III patients. We used an independent cohort of melanoma patients to test the extent to which AJCC8 has improved prognostic accuracy compared with AJCC7. Methods We analyzed a cohort of 1315 prospectively enrolled patients. We assessed primary tumor and nodal classification of stage I–III patients using AJCC7 and AJCC8 to assign disease stages at diagnosis. We compared recurrence-free (RFS) and overall survival (OS) using Kaplan-Meier curves and log-rank tests. We then compared concordance indices of discriminatory prognostic ability and area under the curve of 5-year survival to predict RFS and OS. All statistical tests were two-sided. Results Stage IIC patients continued to have worse outcomes than stage IIIA patients, with a 5-year RFS of 26.5% (95% confidence interval [CI] = 12.8% to 55.1%) vs 56.0% (95% CI = 37.0% to 84.7%) by AJCC8 (P = .002). For stage I, removing mitotic index as a T classification factor decreased its prognostic value, although not statistically significantly (RFS concordance index [C-index] = 0.63, 95% CI = 0.56 to 0.69; to 0.56, 95% CI = 0.49 to 0.63, P = .07; OS C-index = 0.48, 95% CI = 0.38 to 0.58; to 0.48, 95% CI = 0.41 to 0.56, P = .90). For stage II, prognostication remained constant (RFS C-index = 0.65, 95% CI = 0.57 to 0.72; OS C-index = 0.61, 95% CI = 0.50 to 0.72), and for stage III, AJCC8 yielded statistically significantly enhanced prognostication for RFS (C-index = 0.65, 95% CI = 0.60 to 0.70; to 0.70, 95% CI = 0.66 to 0.75, P = .01). Conclusions Compared with AJCC7, we demonstrate that AJCC8 enables more accurate prognosis for patients with stage III melanoma. Restaging a large cohort of patients can enhance the analysis of active clinical trials.

Sign in / Sign up

Export Citation Format

Share Document